INNATE PHARMA financials
INNATE PHARMA
9695002Y8420ZB8HJE29 | Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | €20.1M | €61.6M |
| Operating expenses | €71.7M | €74.3M |
| Operating profit (EBIT) | -€51.6M | -€12.7M |
| Net finance income / (cost) | €2.1M | €5.1M |
| Finance costs | €4.0M | €1.8M |
| Profit before tax | -€49.5M | -€7.6M |
| Income tax expense | €0 | €0 |
| Profit for the year | -€49.5M | -€7.6M |
| Total comprehensive income | -€49.9M | -€6.9M |
| Per share | ||
| Basic EPS | €-0.61 | €-0.09 |
| Diluted EPS | €-0.61 | €-0.09 |
| Free cash flow / share | €-0.09 | €-0.41 |
| Cash flow statement | ||
| Net cash from operating activities | -€6.9M | -€32.6M |
| Net cash from investing activities | €9.2M | €20.6M |
| Purchase of PP&E (capex) | €391.0K | €351.0K |
| Purchase of intangibles | €0 | €2.0M |
| Net cash from financing activities | -€6.0M | -€2.0M |
| Balance sheet | ||
| Total assets | €111.1M | €175.2M |
| Non-current assets | €25.3M | €27.2M |
| Current assets | €85.7M | €148.0M |
| Trade & other receivables | €5.0M | €55.6M |
| Cash & equivalents | €66.4M | €70.6M |
| Total equity | €8.8M | €51.9M |
| Non-current liabilities | €69.2M | €83.7M |
| Current liabilities | €33.0M | €39.6M |
| Trade & other payables | €16.0M | €17.0M |
| Derived metrics | ||
| Free cash flow | -€7.3M | -€32.9M |
| Operating margin | -256.3% | -20.6% |
| Net margin | -245.9% | -12.3% |
| Return on equity | -560.0% | -14.6% |
| Cash conversion ratio | 0.14× | 4.30× |
| Capex coverage | -17.64× | -92.76× |
| Other reported items | ||
| Accumulated Other Comprehensive Income | €27.0K | €495.0K |
| Adjusted Weighted Average Shares | 81.1M | 80.5M |
| Adjustments For Decrease Increase In Trade and Other Receivables | €51.8M | -€13.7M |
| Adjustments For Fair Value Gains Losses | -€1.3M | -€1.6M |
| Adjustments For Finance Income | €0 | €991.0K |
| Adjustments For Increase Decrease In Deferred Income Including Contract Liabilities | -€7.0M | -€4.0M |
| Adjustments For Increase Decrease In Employee Benefit Liabilities | €324.0K | €285.0K |
| Adjustments For Increase Decrease In Trade and Other Payables | -€1.0M | -€3.9M |
| Adjustments For Losses Gains On Disposal of Noncurrent Assets | €20.0K | €470.0K |
| Adjustments For Sharebased Payments | €3.9M | €4.3M |
| Adjustments For Unrealised Foreign Exchange Losses Gains | -€885.0K | €544.0K |
| Basic Earnings Loss Per Share From Continuing Operations | €-0.61 | €-0.09 |
| Basic Earnings Loss Per Share From Discontinued Operations | €0.00 | €0.00 |
| Cash Flows From Used In Operations Before Changes In Working Capital | -€46.1M | -€467.0K |
| Current Contract Liabilities | €616.0K | €5.9M |
| Current Financial Assets | €14.4M | €21.9M |
| Current Financial Liabilities | €8.7M | €8.9M |
| Current Provisions | €207.0K | €171.0K |
| Deferred Income Including Contract Liabilities | €3.4M | €10.5M |
| Diluted Earnings Loss Per Share From Continuing Operations | €-0.61 | €-0.09 |
| Diluted Earnings Loss Per Share From Discontinued Operations | €0.00 | €0.00 |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -€505.0K | €274.0K |
| Equity and Liabilities | €111.1M | €175.2M |
| Finance Income | €6.1M | €6.9M |
| Increase Decrease In Cash and Cash Equivalents | -€4.2M | -€13.6M |
| Increase Decrease In Working Capital | -€39.2M | €32.1M |
| Increase Decrease Through Appropriation of Retained Earnings | €0 | €0 |
| Increase Decrease Through Sharebased Payment Transactions | €3.9M | €4.3M |
| Intangible Assets Other Than Goodwill | €0 | €416.0K |
| Interest Paid Classified As Operating Activities | €1.3M | €600.0K |
| Interest Received Classified As Operating Activities | €1.9M | €2.2M |
| Issue of Equity | €2.8M | €0 |
| Issued Capital | €4.2M | €4.0M |
| Noncurrent Contract Liabilities | €2.8M | €4.6M |
| Noncurrent Financial Assets | €10.3M | €9.8M |
| Noncurrent Financial Liabilities | €22.3M | €31.0M |
| Noncurrent Provisions | €274.0K | €603.0K |
| Noncurrent Provisions For Employee Benefits | €2.7M | €2.4M |
| Noncurrent Receivables | €9.3M | €10.6M |
| Other Adjustments To Reconcile Profit Loss | €24.0K | €6.0K |
| Other Comprehensive Income | -€468.0K | €670.0K |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | -€504.0K | €276.0K |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | €36.0K | €394.0K |
| Other Noncurrent Nonfinancial Assets | €575.0K | €87.0K |
| Proceeds From Other Longterm Assets Classified As Investing Activities | €0 | €66.0K |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | €0 | €150.0K |
| Profit Loss From Continuing Operations | -€49.5M | -€7.6M |
| Purchase of Other Longterm Assets Classified As Investing Activities | €0 | €3.0K |
| Research and Development Expense | €52.0M | €56.0M |
| Retained Earnings Excluding Profit Loss For Reporting Period | -€336.9M | -€329.3M |
| Retained Earnings Profit Loss For Reporting Period | -€49.5M | -€7.6M |
| Revenue From Contracts With Customers | €12.6M | €51.9M |
| Revenue From Government Grants | €7.5M | €9.7M |
| Revenue From Sale of Goods | €11.0K | €11.0K |
| Selling General and Administrative Expense | €19.7M | €18.3M |
| Share Premium | €391.0M | €384.3M |
| Trade and Other Payables | €16.0M | €17.0M |
| Trade and Other Receivables | €14.3M | €66.1M |
Every line item above is a fact tagged in INNATE PHARMA's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.